toro albala montilla moriles

Description: Naphazoline hydrochloride, an ocular vasoconstrictor, is an imidazolinederivative sympathomimetic amine toro albala montilla moriles. It occurs as a white, odorless crystallinepowder having a bitter taste and is freely soluble in water and in alcohol toro albala montilla moriles.

Chemical Name: 2-(1-Naphthylmethyl)-2-imidazoline monohydrochloride

Contains:

Active: naphazoline HCl 0.1% toro albala montilla moriles. Preservative: benzalkonium chloride 0.004% toro albala montilla moriles.

Inactives: citric acid, monohydrate; edetate disodium; polyvinyl alcohol 1.4%;purified water; sodium chloride; sodium citrate, dihydrate; and sodium hydroxideto adjust the pH toro albala montilla moriles. It has a shelf life pH range of 5.5 to 6.5 toro albala montilla moriles.

Clinical Pharmacology: Naphazoline constricts the vascular system of the conjunctiva toro albala montilla moriles. It is presumed that this effect is due to direct stimulation action of the drugupon the alpha-adrenergic receptors in the arterioles of the conjunctiva, resultingin decreased conjunctival congestion toro albala montilla moriles. Naphazoline belongs to the imidazolineclass of sympathomimetics toro albala montilla moriles.

Indications and Usage: ALBALON® (naphazoline hydrochloride ophthalmic solution,USP) 0.1% is indicated for use as a topical ocular vasoconstrictor toro albala montilla moriles.

Contraindications: ALBALON® ophthalmic solution is contraindicated in thepresence of an anatomically narrow angle or in narrow-angle glaucoma or in personswho have shown hypersensitivity to any component of this preparation toro albala montilla moriles.

Warnings: Patients under therapy with MAO inhibitors may experience a severehypertensive crisis if given a sympathomimetic drug toro albala montilla moriles. Use in children, especiallyinfants, may result in CNS depression leading to coma and marked reduction inbody temperature toro albala montilla moriles.

Precautions:

General: Use with caution in the presence of hypertension, cardiovascular abnormalities,hyperglycemia (diabetes), hyperthyroidism, infection or injury toro albala montilla moriles.

Patient Information: Patients should be advised to discontinue the drug andconsult a physician if relief is not obtained within 48 hours of therapy, ifirritation, blurring or redness persists or increases, or if symptoms of systemicabsorption occur, i.e., dizziness, headache, nausea, decrease in body temperature,or drowsiness toro albala montilla moriles.

To prevent contaminating the dropper tip and solution, do not touch the eyelidsor the surrounding area with the dropper tip of the bottle toro albala montilla moriles. If solution changescolor or becomes cloudy, do not use toro albala montilla moriles.

Drug Interactions: Concurrent use of maprotiline or tricyclic antidepressantsand naphazoline may potentiate the pressor effect of naphazoline toro albala montilla moriles. Patients undertherapy with MAO inhibitors may experience a severe hypertensive crisis if givena sympathomimetic drug toro albala montilla moriles. (See Warnings ) toro albala montilla moriles.

Pregnancy: Pregnancy Category C: Animal reproduction studies have not beenconducted with naphazoline toro albala montilla moriles. It is also not known whether naphazoline can causefetal harm when administered to a pregnant woman or can affect reproductioncapacity toro albala montilla moriles. Naphazoline should be given to a pregnant woman only if clearly needed toro albala montilla moriles.

Nursing Mothers: It is not known whether naphazoline is excreted in human milk toro albala montilla moriles. Because many drugs are excreted in human milk, caution should be exercised whennaphazoline is administered to a nursing woman toro albala montilla moriles.

Pediatric Use: Safety and effectiveness in pediatric patients have not beenestablished toro albala montilla moriles. See " Warnings " AND " Contraindications ."

Adverse Reactions:

Ocular: Mydriasis, increased redness, irritation, discomfort, blurring, punctatekeratitis, lacrimation, increased intraocular pressure toro albala montilla moriles.

Systemic: Dizziness, headache, nausea, sweating, nervousness, drowsiness, weakness,hypertension, cardiac irregularities, and hyperglycemia toro albala montilla moriles.

Dosage and Administration: Instill one or two drops in the conjunctival sac(s)every three to four hours as needed toro albala montilla moriles.

How Supplied: ALBALON® (naphazoline hydrochloride ophthalmic solution, USP)0.1% is supplied sterile in opaque white LDPE plastic bottles with dropper tipsand white high impact polystyrene (HIPS) caps as follows:

15 mL in 15 mL bottle - NDC 11980-154-15

Note: Store between 15° to 25°C (59° to 77°F) toro albala montilla moriles.

Rx only

Copyright 2005 D-S LTD.
All Rights Reserved.